This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
lung injury | 1262 |
lung cancer | 1226 |
cystic fibrosis | 1211 |
lung disease | 1001 |
lung transplantation | 803 |
epithelial cells | 759 |
lung function | 758 |
acute respiratory | 702 |
respiratory distress | 645 |
acute lung | 578 |
lung transplant | 564 |
pulmonary fibrosis | 562 |
distress syndrome | 555 |
transplant recipients | 527 |
respiratory tract | 466 |
pulmonary disease | 436 |
lung diseases | 380 |
lung tissue | 351 |
stem cells | 348 |
alveolar macrophages | 348 |
mechanical ventilation | 337 |
pulmonary function | 324 |
infl uenza | 319 |
interstitial pneumonia | 318 |
induced lung | 308 |
chronic obstructive | 307 |
respiratory failure | 297 |
type ii | 293 |
idiopathic pulmonary | 290 |
obstructive pulmonary | 286 |
immune response | 285 |
smooth muscle | 283 |
bronchoalveolar lavage | 282 |
may also | 271 |
risk factors | 269 |
bone marrow | 262 |
influenza virus | 258 |
interstitial lung | 257 |
gene expression | 256 |
human lung | 246 |
airway epithelial | 243 |
avian infl | 241 |
growth factor | 238 |
lymph nodes | 235 |
inflammatory response | 225 |
cell lung | 222 |
oxidative stress | 217 |
acute rejection | 207 |
nitric oxide | 205 |
virus infection | 202 |
respiratory system | 201 |
bronchiolitis obliterans | 199 |
pulmonary edema | 198 |
pseudomonas aeruginosa | 197 |
mean age | 197 |
stem cell | 193 |
endothelial cells | 190 |
mg kg | 190 |
pulmonary hypertension | 189 |
chronic lung | 183 |
dendritic cells | 181 |
viral infections | 179 |
pleural effusion | 177 |
small cell | 173 |
cell lines | 173 |
lung parenchyma | 173 |
mesenchymal stem | 168 |
epithelial cell | 167 |
airway inflammation | 167 |
lung volume | 166 |
ex vivo | 164 |
lung inflammation | 163 |
immune responses | 163 |
severe acute | 162 |
see chapter | 161 |
doc id | 160 |
cord uid | 160 |
type i | 159 |
clinical trials | 159 |
respiratory disease | 157 |
ct scan | 156 |
lung adenocarcinoma | 154 |
infl ammation | 154 |
diffuse alveolar | 150 |
copd patients | 149 |
intensive care | 148 |
bronchial epithelial | 148 |
respiratory syncytial | 146 |
chest wall | 145 |
inflammatory cytokines | 144 |
animal models | 144 |
syncytial virus | 143 |
gas exchange | 143 |
cell types | 142 |
increased risk | 142 |
alveolar epithelial | 137 |
immune system | 137 |
respiratory syndrome | 137 |
lung tissues | 137 |
important role | 137 |
viral infection | 135 |
respiratory symptoms | 134 |
fi brosis | 133 |
lower respiratory | 132 |
necrosis factor | 131 |
lung fibrosis | 131 |
pulmonary surfactant | 131 |
united states | 130 |
airway obstruction | 130 |
alveolar damage | 129 |
pulmonary artery | 128 |
gene therapy | 126 |
cancer cells | 126 |
solid organ | 125 |
clinical practice | 125 |
respiratory diseases | 125 |
drug delivery | 125 |
lung allograft | 124 |
cigarette smoke | 124 |
lung biopsy | 123 |
mouse model | 123 |
cancer patients | 122 |
tidal volume | 121 |
airway smooth | 121 |
induced pulmonary | 120 |
inflammatory cells | 117 |
small airways | 117 |
fi ndings | 116 |
computed tomography | 116 |
control group | 116 |
tumor cells | 116 |
airway epithelium | 114 |
lower lung | 114 |
ground glass | 113 |
lavage fluid | 113 |
severe asthma | 112 |
data suggest | 112 |
may occur | 112 |
innate immune | 111 |
peripheral blood | 110 |
tumor necrosis | 110 |
pulmonary alveolar | 110 |
upper respiratory | 108 |
lung slices | 108 |
ali ards | 108 |
bacterial pneumonia | 107 |
mycobacterium tuberculosis | 107 |
surfactant protein | 107 |
immune cells | 107 |
progenitor cells | 107 |
respiratory infections | 106 |
blood vessels | 106 |
connective tissue | 106 |
young children | 105 |
case report | 105 |
gene transfer | 105 |
systematic review | 105 |
chest pain | 105 |
liver disease | 104 |
differential diagnosis | 103 |
uenza virus | 103 |
cell line | 103 |
healthy controls | 103 |
critically ill | 102 |
infectious diseases | 102 |
organ transplant | 101 |
high levels | 101 |
clinical trial | 100 |
side effects | 100 |
rheumatoid arthritis | 100 |
mouse lung | 100 |
human airway | 100 |
fungal infections | 99 |
recent studies | 99 |
reperfusion injury | 99 |
chest ct | 99 |
normal lung | 99 |
weight loss | 99 |
cell surface | 98 |
nucleic acid | 98 |
asthma control | 97 |
mucociliary clearance | 97 |
may cause | 97 |
significant difference | 97 |
long term | 96 |
transplant patients | 96 |
cell carcinoma | 96 |
risk factor | 95 |
squamous cell | 95 |
lymph node | 93 |
disease severity | 93 |
airway resistance | 92 |
adult patients | 92 |
fev predicted | 92 |
airway pressure | 92 |
organizing pneumonia | 92 |
glass opacity | 92 |
cell count | 91 |
commonly used | 91 |
lung development | 91 |
clinical features | 90 |
cell proliferation | 90 |
present study | 90 |
significant differences | 90 |
mrna expression | 90 |
obliterans syndrome | 89 |
results suggest | 89 |
staphylococcus aureus | 89 |
may result | 89 |
bacterial infection | 89 |
lung pathology | 89 |
lung microbiome | 89 |
pulmonary infection | 89 |
histologic study | 88 |
reactive oxygen | 88 |
heart transplant | 88 |
lung epithelial | 87 |
pleural effusions | 87 |
airway wall | 87 |
controlled trial | 87 |
pulmonary vascular | 86 |
alveolar proteinosis | 86 |
early stage | 85 |
lung volumes | 85 |
cell death | 85 |
ii cells | 85 |
oxygen species | 85 |
bacterial infections | 85 |
significantly higher | 85 |
extracellular matrix | 85 |
performed using | 85 |
hiv aids | 84 |
electron microscopy | 84 |
see also | 84 |
statistically significant | 84 |
health care | 84 |
allograft rejection | 83 |
pulmonary inflammation | 83 |
lung mechanics | 83 |
nasal cavity | 83 |
hypersensitivity pneumonitis | 83 |
flow cytometry | 83 |
alveolar epithelium | 82 |
human infected | 82 |
superoxide dismutase | 82 |
respiratory viral | 82 |
chronic bronchitis | 81 |
hyaline membranes | 81 |
care unit | 81 |
pulmonary diseases | 81 |
severe cases | 81 |
upper airway | 81 |
randomized controlled | 81 |
infl ammatory | 80 |
heart failure | 80 |
patients may | 80 |
first year | 80 |
measured using | 80 |
alveolar walls | 80 |
diabetes mellitus | 80 |
significantly reduced | 80 |
associated conditions | 80 |
glass opacities | 80 |
high risk | 80 |
pleural space | 79 |
cohort study | 79 |
forced expiratory | 79 |
pluripotent stem | 79 |
body weight | 79 |
interstitial fibrosis | 79 |
clinical symptoms | 79 |
possible associated | 78 |
may contribute | 78 |
nutritional status | 78 |
recent study | 77 |
transforming growth | 77 |
pg ml | 77 |
lung ultrasound | 77 |
function tests | 77 |
lung cancers | 77 |
ng ml | 77 |
lung infection | 77 |
alveolar type | 76 |
human beings | 76 |
basement membrane | 76 |
alveolar macrophage | 76 |
asm cells | 76 |
tidal breathing | 76 |
significantly increased | 75 |
injured lungs | 75 |
pulmonary infections | 75 |
alveolar septa | 75 |
lymphoid tissue | 75 |
giant cells | 74 |
endothelial cell | 74 |
transcription factor | 74 |
right lung | 74 |
pulmonary arterial | 74 |
inflammatory responses | 74 |
defense mechanisms | 74 |
memory cd | 74 |
nucleic acids | 74 |
blood gas | 74 |
plasma membrane | 73 |
disease progression | 73 |
airway hyperresponsiveness | 73 |
rm cells | 73 |
protein expression | 73 |
alveolar space | 73 |
lung perfusion | 73 |
obliterative bronchiolitis | 72 |
airway disease | 72 |
coronavirus disease | 72 |
specimen preparation | 72 |
clinical manifestations | 71 |
mononuclear cells | 71 |
airway epithelia | 71 |
cftr gene | 70 |
blood flow | 70 |
least one | 70 |
vascular permeability | 70 |
airflow obstruction | 70 |
lung damage | 69 |
well tolerated | 69 |
mortality rate | 69 |
inflammatory mediators | 69 |
rhodococcus equi | 69 |
mean fev | 69 |
cell culture | 69 |
induced acute | 68 |
obstructive sleep | 68 |
obstructive lung | 68 |
expiratory flow | 68 |
cftr protein | 68 |
muscle cells | 68 |
pulmonary delivery | 68 |
transmembrane conductance | 68 |
fatty acids | 68 |
may lead | 68 |
expected findings | 68 |
chronic inflammation | 67 |
common cause | 67 |
spontaneous breathing | 67 |
bronchopulmonary dysplasia | 67 |
respiratory virus | 67 |
antibiotic therapy | 66 |
mg ml | 66 |
lung microbiota | 66 |
expiratory pressure | 66 |
significant increase | 66 |
stem progenitor | 66 |
aged years | 66 |
respiratory function | 66 |
newborn screening | 66 |
novel coronavirus | 66 |
one patient | 66 |
respiratory viruses | 66 |
regional strain | 66 |
conductance regulator | 66 |
cells may | 66 |
nuclear factor | 65 |
adult respiratory | 65 |
infi ltration | 65 |
function testing | 65 |
respiratory mechanics | 65 |
upper lobe | 65 |
aids related | 65 |
ill patients | 65 |
fl uid | 64 |
chest radiographs | 64 |
human bronchial | 64 |
cytokine production | 64 |
related terms | 64 |
body temperature | 64 |
significantly lower | 64 |
ciliated cells | 64 |
chest radiograph | 63 |
also known | 63 |
rat lung | 62 |
eosinophilic pneumonia | 62 |
hypertonic saline | 62 |
sleep apnea | 62 |
external examination | 62 |
ct scanning | 62 |
preterm infants | 62 |
protein kinase | 62 |
years old | 62 |
tissue culture | 62 |
sputum samples | 62 |
allograft dysfunction | 62 |
fev fvc | 61 |
extracorporeal membrane | 61 |
also found | 61 |
lower lobe | 61 |
clinical presentation | 61 |
left lung | 61 |
pneumocystis carinii | 61 |
thoracic society | 61 |
ml kg | 61 |
influenza infection | 61 |
ards patients | 61 |
pulmonary toxicity | 61 |
defi ned | 61 |
following lung | 60 |
arterial blood | 60 |
pulmonary tuberculosis | 60 |
signifi cant | 60 |
fibrosis patients | 60 |
endoplasmic reticulum | 60 |
prospective study | 60 |
proinflammatory cytokines | 60 |
airway surface | 60 |
viral pneumonia | 60 |
membrane oxygenation | 59 |
preschool children | 59 |
neutrophil elastase | 59 |
acquired pneumonia | 59 |
fibrosis transmembrane | 59 |
phase ii | 59 |
sex hormones | 59 |
pulmonary interstitial | 59 |
fi rst | 59 |
stromal cells | 59 |
surface tension | 59 |
control subjects | 59 |
pilot study | 59 |
positive end | 59 |
leading cause | 59 |
chronic inflammatory | 58 |
cell cycle | 58 |
animal model | 58 |
like receptor | 58 |
murine model | 58 |
cftr expression | 58 |
widely used | 58 |
host defense | 58 |
adverse effects | 58 |
submit samples | 57 |
pulmonary exacerbations | 57 |
international society | 57 |
pediatric patients | 57 |
oxygen saturation | 57 |
pulmonary arteries | 57 |
may play | 57 |
pulmonary embolism | 57 |
primary lung | 57 |
increased levels | 57 |
mesenchymal stromal | 57 |
determine whether | 57 |
many patients | 57 |
pulmonary lesions | 56 |
cftr function | 56 |
cancer cell | 56 |
clinical studies | 56 |
dendritic cell | 56 |
lung slice | 56 |
childhood asthma | 56 |
lung lobe | 56 |
pathological changes | 56 |
carbon monoxide | 56 |
inhaled corticosteroids | 56 |
organ transplantation | 56 |
antibiotic treatment | 56 |
nervous system | 56 |
carbon dioxide | 56 |
heart disease | 56 |
pulmonary exacerbation | 56 |
early diagnosis | 56 |
serum levels | 56 |
clinical course | 55 |
fatty acid | 55 |
several studies | 55 |
marrow transplantation | 55 |
skeletal muscle | 55 |
resolution ct | 55 |
bal fluid | 55 |
spinal cord | 55 |
aids patients | 55 |
laboratory animals | 54 |
alveolar hemorrhage | 54 |
mouse models | 54 |
lung cells | 54 |
transplant recipient | 54 |
lung lobes | 54 |
patients treated | 54 |
tyrosine kinase | 54 |
clinical signs | 54 |
donor lungs | 54 |
htv ventilation | 54 |
cell differentiation | 54 |
pneumonia induced | 54 |
previously described | 54 |
lung abscess | 54 |
diffuse interstitial | 54 |
secondary bacterial | 53 |
dependent manner | 53 |
surface area | 53 |
air pollution | 53 |
heart rate | 53 |
cell type | 53 |
blood pressure | 53 |
united kingdom | 53 |
immunodeficiency virus | 53 |
innate immunity | 53 |
tidal volumes | 53 |
wide range | 53 |
severe lung | 53 |
cell hyperplasia | 53 |
systemic sclerosis | 53 |
air trapping | 52 |
foreign body | 52 |
wild type | 52 |
inflammatory cell | 52 |
may help | 52 |
inflammatory process | 52 |
tract infections | 52 |
small airway | 52 |
transbronchial biopsy | 52 |
patients without | 52 |
chronic rejection | 52 |
chloride channel | 52 |
mast cells | 52 |
chronic respiratory | 52 |
fibrosis foundation | 52 |
vivo lung | 52 |
protein levels | 51 |
associated lung | 51 |
ii pneumocytes | 51 |
cytokine storm | 51 |
pulmonary rehabilitation | 51 |
clinical outcomes | 51 |
human lungs | 51 |
world health | 51 |
growth factors | 51 |
one study | 51 |
lung fi | 51 |
streptococcus pneumoniae | 51 |
year old | 51 |
syndrome coronavirus | 50 |
acute interstitial | 50 |
inflammatory diseases | 50 |
interstitial pneumonias | 50 |
airway caliber | 50 |
infected lung | 50 |
general population | 50 |
sweat chloride | 50 |
high mortality | 50 |
signifi cantly | 50 |
pulmonary drug | 50 |
respiratory muscle | 50 |
adult lung | 50 |
less common | 50 |
blood cells | 50 |
lung infections | 50 |
respiratory drive | 49 |
expiratory volume | 49 |
graft dysfunction | 49 |
aspiration pneumonia | 49 |
amino acid | 49 |
signaling pathways | 49 |
hand column | 49 |
class i | 49 |
infected patients | 49 |
submucosal glands | 49 |
respiratory infection | 49 |
dry powder | 49 |
delivery systems | 49 |
ct scans | 49 |
healthy subjects | 48 |
severe disease | 48 |
antitrypsin deficiency | 48 |
respiratory rate | 48 |
total lung | 48 |
apical membrane | 48 |
lung rejection | 48 |
monoclonal antibody | 48 |
allergic asthma | 48 |
asm strain | 48 |
soft tissue | 48 |
significantly different | 47 |
sirna delivery | 47 |
acute pulmonary | 47 |
critical care | 47 |
cell carcinomas | 47 |
findings suggest | 47 |
viral vectors | 47 |
tissue damage | 47 |
aspergillus fumigatus | 47 |
previous studies | 47 |
gene silencing | 47 |
infection control | 47 |
two groups | 47 |
high resolution | 47 |
barrier function | 47 |
chest tube | 47 |
vascular endothelial | 47 |
young adults | 47 |
clara cells | 47 |
molecular mechanisms | 47 |
delivery system | 47 |
knockout mice | 47 |
pao fio | 47 |
nasal mucosa | 47 |
cell histiocytosis | 47 |
recent years | 47 |
reduced lung | 47 |
pulmonary involvement | 47 |
malignant pleural | 46 |
prone position | 46 |
early stages | 46 |
ii pneumonocytes | 46 |
wt mice | 46 |
clinical characteristics | 46 |
inflammatory cytokine | 46 |
ct findings | 46 |
adhesion molecule | 46 |
surface liquid | 46 |
among patients | 46 |
fungal infection | 46 |
factor receptor | 46 |
study showed | 46 |
transcription factors | 46 |
human infection | 46 |
respiratory epithelium | 46 |
two different | 46 |
severe ards | 46 |
another study | 46 |
inflammatory lung | 46 |
time pcr | 46 |
spontaneous pneumothorax | 46 |
lung lesions | 45 |
fold increase | 45 |
conducting airways | 45 |
hydrogen peroxide | 45 |
disordered breathing | 45 |
may show | 45 |
cd cd | 45 |
lung ischemia | 45 |
ventilation heterogeneity | 45 |
evidence suggests | 45 |
ischemia reperfusion | 45 |
right lower | 45 |
pulmonary oedema | 45 |
respiratory health | 45 |
mass index | 45 |
muc ac | 45 |
body mass | 45 |
basal cells | 45 |
adverse events | 45 |
diagnostic criteria | 45 |
natural killer | 45 |
physical activity | 45 |
human respiratory | 44 |
controlled trials | 44 |
ion transport | 44 |
histochemically detected | 44 |
pathologic findings | 44 |
functional residual | 44 |
ciliary dyskinesia | 44 |
cell function | 44 |
studies suggest | 44 |
detected activity | 44 |
disease caused | 44 |
rnai molecules | 44 |
human immunodeficiency | 44 |
pleural mesothelioma | 44 |
infected cells | 44 |
critical role | 44 |
adaptive immune | 44 |
phase iii | 44 |
submit sample | 44 |
systemic lupus | 44 |
procedures depend | 44 |
sex differences | 44 |
infectious disease | 44 |
oxide synthase | 44 |
also cause | 44 |
herpes simplex | 44 |
therapeutic targets | 44 |
single cell | 44 |
may develop | 44 |
therapeutic potential | 44 |
left lower | 44 |
alveolar wall | 43 |
oxygen therapy | 43 |
lower airway | 43 |
cu zn | 43 |
chain reaction | 43 |
septal thickening | 43 |
room temperature | 43 |
different lung | 43 |
practice guidelines | 43 |
residual capacity | 43 |
old man | 43 |
lung samples | 43 |
protective ventilation | 43 |
pulmonary complications | 43 |
increased expression | 43 |
vena cava | 43 |
lipoid pneumonia | 43 |
systemic inflammation | 43 |
parenchymal changes | 43 |
exercise capacity | 43 |
pulmonary parenchyma | 43 |
invasive aspergillosis | 43 |
health organization | 43 |
study group | 43 |
glutathione peroxidase | 43 |
amino acids | 43 |
goblet cells | 43 |
copd subjects | 43 |
signaling pathway | 43 |
lung compliance | 43 |
ir group | 42 |
lupus erythematosus | 42 |
two patients | 42 |
significantly decreased | 42 |
severe pneumonia | 42 |
distal lung | 42 |
organ failure | 42 |
age years | 42 |
related pulmonary | 42 |
wound healing | 42 |
right ventricular | 42 |
single lung | 42 |
dry cough | 42 |
escherichia coli | 42 |
gene delivery | 42 |
collagen deposition | 42 |
respiratory bronchioles | 42 |
severe covid | 42 |
consecutive patients | 42 |
plasma cells | 42 |
inflamed lungs | 42 |
clinical data | 42 |
free radicals | 42 |
chronic cough | 42 |
polymerase chain | 42 |
liquid interface | 42 |
cryptococcus neoformans | 42 |
endothelial barrier | 42 |
upper lung | 42 |
high fever | 42 |
cell membrane | 42 |
expression levels | 42 |
previously reported | 41 |
infection may | 41 |
primary pulmonary | 41 |
lps administration | 41 |
airways disease | 41 |
poorly defined | 41 |
lung allografts | 41 |
month period | 41 |
current asthma | 41 |
pediatric lung | 41 |
renal failure | 41 |
grossly identified | 41 |
tumor growth | 41 |
acute exacerbation | 41 |
early life | 41 |
stimulating factor | 41 |
medical history | 41 |
positive cells | 41 |
alveolar spaces | 41 |
even though | 41 |
interstitial pneumonitis | 41 |
patients undergoing | 41 |
differentially expressed | 41 |
cmv infection | 41 |
langerhans cell | 41 |
asthmatic patients | 41 |
key role | 41 |
hyaline membrane | 41 |
peak flow | 41 |
igg liposomes | 41 |
septal defect | 41 |
middle lobe | 40 |
bronchial epithelium | 40 |
early childhood | 40 |
radiation therapy | 40 |
molecular weight | 40 |
retrospective study | 40 |
impedance tomography | 40 |
diseases including | 40 |
western blot | 40 |
smoking history | 40 |
ca i | 40 |
driving pressure | 40 |
air embolism | 40 |
logistic regression | 40 |
patients receiving | 40 |
reactive protein | 40 |
pulmonary fi | 40 |
determined using | 40 |
commercially available | 40 |
thoracic cavity | 40 |
identified abnormalities | 40 |
lower lobes | 40 |
gold standard | 40 |
cell transplantation | 40 |
per year | 40 |
may provide | 40 |
acid aspiration | 40 |
cigarette smoking | 40 |
pulmonary hemorrhage | 40 |
taken together | 39 |
ray demonstrates | 39 |
converting enzyme | 39 |
regional lung | 39 |
surfactant system | 39 |
giant cell | 39 |
airflow limitation | 39 |
cftr mutations | 39 |
overall survival | 39 |
lung macrophages | 39 |
smoking cessation | 39 |
action plan | 39 |
productive cough | 39 |
cell apoptosis | 39 |
goblet cell | 39 |
lipid peroxidation | 39 |
asthma exacerbations | 39 |
interfering rna | 39 |
may represent | 39 |
poor prognosis | 39 |
patients received | 39 |
electrical impedance | 39 |
surfactant proteins | 39 |
septic shock | 39 |
pleural cavity | 39 |
animal studies | 39 |
osa patients | 39 |
mechanically ventilated | 39 |
upper lobes | 38 |
stable ltxrs | 38 |
hospital admission | 38 |
first months | 38 |
rv infection | 38 |
adipose tissue | 38 |
median survival | 38 |
public health | 38 |
squamous metaplasia | 38 |
increased mortality | 38 |
patients admitted | 38 |
clinical outcome | 38 |
standard deviation | 38 |
emergency department | 38 |
associated lymphoid | 38 |
airway remodelling | 38 |
lipid metabolism | 38 |
respiratory support | 38 |
beneficial effects | 38 |
disease control | 38 |
left upper | 38 |
tumor suppressor | 38 |
pulmonary pathology | 38 |
ipf patients | 38 |
epidermal growth | 38 |
study period | 38 |
primary ciliary | 38 |
oscillation technique | 38 |
lung metastasis | 38 |
granulation tissue | 38 |
asl volume | 38 |
preliminary results | 38 |
significant improvement | 38 |
cells expressing | 38 |
zn sod | 38 |
rna interference | 38 |
year survival | 37 |
current study | 37 |
pulmonary aspergillosis | 37 |
low levels | 37 |
induced sputum | 37 |
multiple organ | 37 |
burkholderia cepacia | 37 |
fl akes | 37 |
vitro studies | 37 |
lung fields | 37 |
wide variety | 37 |
median age | 37 |
vital capacity | 37 |
chronic pulmonary | 37 |
type cftr | 37 |
immune cell | 37 |
forced oscillation | 37 |
cell counts | 37 |
mg dl | 37 |
host response | 37 |
multinucleated giant | 37 |
cftr activity | 37 |
cd cells | 37 |
airway remodeling | 37 |
pulmonary blood | 37 |
diffusing capacity | 37 |
asbestos exposure | 37 |
central nervous | 37 |
children aged | 37 |
usual interstitial | 37 |
heart transplantation | 37 |
positive pressure | 37 |
based therapies | 37 |
experimental studies | 37 |
lipid pneumonia | 37 |
lung weight | 37 |
high dose | 37 |
time points | 37 |
laboratory tests | 37 |
major cause | 36 |
lower airways | 36 |
asthma symptoms | 36 |
replacement therapy | 36 |
idiopathic interstitial | 36 |
also observed | 36 |
results showed | 36 |
potential difference | 36 |
rsv infection | 36 |
data indicate | 36 |
severe pulmonary | 36 |
therapeutic strategies | 36 |
pulmonary injury | 36 |
many years | 36 |
one year | 36 |
related diabetes | 36 |
gas analysis | 36 |
visceral pleura | 36 |
observational study | 36 |
positive airway | 36 |
future studies | 36 |
cell population | 36 |
airway clearance | 36 |
cell subsets | 36 |
asthmatic subjects | 36 |
highly pathogenic | 36 |
weight gain | 36 |
also present | 36 |
coronary artery | 36 |
virus replication | 36 |
chest imaging | 36 |
ko mice | 36 |
associated pneumonia | 36 |
binding protein | 36 |
pasteurella multocida | 36 |
pleural fluid | 36 |
increased airway | 36 |
apical surface | 35 |
patients infected | 35 |
magnetic resonance | 35 |
lamellar bodies | 35 |
imaging studies | 35 |
identifi ed | 35 |
hyperacute rejection | 35 |
mutant cftr | 35 |
case series | 35 |
american thoracic | 35 |
inhalation therapy | 35 |
physical examination | 35 |
asthma severity | 35 |
clinical assessment | 35 |
barr virus | 35 |
poorly understood | 35 |
adhesion molecules | 35 |
th cells | 35 |
first time | 35 |
diffi cult | 35 |
respiratory effort | 35 |
pa infection | 35 |
radiation exposure | 35 |
lung epithelium | 35 |
inflammatory bowel | 35 |
air bronchogram | 35 |
transgenic mice | 35 |
arterial hypertension | 35 |
cell cultures | 35 |
macrophage activation | 35 |
host disease | 35 |
lung biopsies | 35 |
oral cavity | 35 |
relatively low | 35 |
laden macrophages | 35 |
lung carcinoma | 35 |
advanced stage | 35 |
protective effects | 35 |
also occur | 35 |
primary human | 35 |
ats ers | 34 |
allergic airway | 34 |
lung markings | 34 |
lung edema | 34 |
cell infiltration | 34 |
potential role | 34 |
red blood | 34 |
potential therapeutic | 34 |
virus infections | 34 |
phase i | 34 |
chest radiography | 34 |
pulmonary endothelial | 34 |
tobacco smoke | 34 |
clinically relevant | 34 |
exhaled breath | 34 |
neutrophil recruitment | 34 |
university hospital | 34 |
quantitative pcr | 34 |
small interfering | 34 |
sweat test | 34 |
treated mice | 34 |
lung involvement | 34 |
parainfluenza virus | 34 |
breath condensate | 34 |
normal range | 34 |
diffuse lung | 34 |
effector cd | 34 |
deficient mice | 34 |
two years | 34 |
better understanding | 34 |
injury induced | 34 |
mass spectrometry | 34 |
pulmonary emphysema | 34 |
cardiovascular disease | 34 |
two cases | 34 |
large number | 34 |
alveolar injury | 34 |
airway diseases | 34 |
desquamative interstitial | 34 |
avian influenza | 34 |
resolution computed | 34 |
family history | 34 |
prone positioning | 34 |
microscopic examination | 34 |
circuit current | 34 |
one lung | 34 |
activated receptor | 33 |
patient aged | 33 |
pressure ventilation | 33 |
survival rate | 33 |
human disease | 33 |
mediastinal lymph | 33 |
normal lungs | 33 |
wbc count | 33 |
clinical setting | 33 |
cell therapy | 33 |
hilar lymph | 33 |
lung tumors | 33 |
interlobular septa | 33 |
results indicate | 33 |
mortality rates | 33 |
cell populations | 33 |
defi ne | 33 |
significant changes | 33 |
higher levels | 33 |
large cell | 33 |
see table | 33 |
ventilated patients | 33 |
cell responses | 33 |
statistical analysis | 33 |
iv antibiotics | 33 |
lung transplants | 33 |
cells within | 33 |
viral replication | 33 |
procedures described | 33 |
malignant mesothelioma | 33 |
persistent asthma | 33 |
large numbers | 33 |
murine lung | 33 |
bl mice | 33 |
viral antigens | 33 |
type diabetes | 33 |
large amounts | 33 |
respiratory medicine | 33 |
embryonic stem | 33 |
representative images | 32 |
cellular uptake | 32 |
interlobular septal | 32 |
birth weight | 32 |
collagen iv | 32 |
rat lungs | 32 |
progenitor cell | 32 |
sample size | 32 |
per day | 32 |
drug resistance | 32 |
left ventricular | 32 |
inclusion criteria | 32 |
viral rna | 32 |
tract infection | 32 |
three times | 32 |
study aimed | 32 |
acute onset | 32 |
rmatively diagnosed | 32 |
acute eosinophilic | 32 |
alveolar cells | 32 |
chronic interstitial | 32 |
pulmonary circulation | 32 |
positively correlated | 32 |
year period | 32 |
airway lumen | 32 |
nonspecific interstitial | 32 |
native lung | 32 |
confi rmatively | 32 |
endothelial growth | 32 |
nk cells | 32 |
pancreatic insufficiency | 32 |
healthy children | 32 |
authors declare | 32 |
acute exacerbations | 32 |
central role | 32 |
disease may | 32 |
allergic bronchopulmonary | 32 |
also seen | 32 |
fi elds | 32 |
delivery vectors | 32 |
least two | 32 |
small molecule | 32 |
stage lung | 32 |
may reflect | 32 |
vagus nerve | 32 |
human metapneumovirus | 32 |
chronic infection | 32 |
blood samples | 32 |
th percentile | 31 |
gastrointestinal tract | 31 |
commonly found | 31 |
often associated | 31 |
influenza viruses | 31 |
bowel disease | 31 |
hematopoietic stem | 31 |
human mesenchymal | 31 |
lung airways | 31 |
pulmonary manifestations | 31 |
channel activity | 31 |
age group | 31 |
phagocytic ability | 31 |
inhaled nitric | 31 |
three patients | 31 |
respiratory pathogens | 31 |
tissue sections | 31 |
amniotic fluid | 31 |
gastroesophageal reflux | 31 |
acute phase | 31 |
protective effect | 31 |
pathologic features | 31 |
inflammatory markers | 31 |
ct imaging | 31 |
ct images | 31 |
chest distress | 31 |
additional file | 31 |
cov infection | 31 |
continuous positive | 31 |
pulmonary infiltrates | 31 |
patients presenting | 31 |
flow rate | 31 |
predicted fev | 31 |
vivo studies | 31 |
mononuclear cell | 31 |
rat model | 31 |
scoring system | 31 |
normal subjects | 31 |
correlation coefficient | 31 |
acute inflammatory | 31 |
pneumonic mannheimiosis | 31 |
viral load | 31 |
within days | 31 |
small number | 31 |
immunocompromised patients | 31 |
high concentrations | 31 |
asthmatic children | 31 |
kg day | 30 |
significantly associated | 30 |
bronchial mucosa | 30 |
deep inspiration | 30 |
vascular diseases | 30 |
often used | 30 |
health outcomes | 30 |
patient population | 30 |
significant decrease | 30 |
severe respiratory | 30 |
therapeutic target | 30 |
human pulmonary | 30 |
studies indicate | 30 |
sirna targeting | 30 |
transbronchial lung | 30 |
survival rates | 30 |
smoke exposure | 30 |
old male | 30 |
fi nding | 30 |
injured lung | 30 |
patients underwent | 30 |
clinically significant | 30 |
lung collapse | 30 |
may become | 30 |
lung growth | 30 |
structural changes | 30 |
slice model | 30 |
lung inflation | 30 |
low risk | 30 |
medical center | 30 |
gastric contents | 30 |
culture medium | 30 |
also reported | 30 |
term survival | 30 |
guinea pigs | 30 |
pathogenic avian | 30 |
allergic disease | 30 |
induced ali | 30 |
supplementary material | 30 |
chronic disease | 30 |
commonly seen | 30 |
cor pulmonale | 30 |
cepacia complex | 30 |
likely due | 30 |
immunodeficiency syndrome | 30 |
mannheimia haemolytica | 30 |
domestic animals | 30 |
environmental factors | 30 |
upper airways | 30 |
stromal cell | 30 |
infectious complications | 30 |
significant reduction | 30 |
airway function | 30 |
right upper | 30 |
acute bronchitis | 30 |
i sc | 30 |
five patients | 30 |
age groups | 30 |
lung capacity | 30 |
branching morphogenesis | 30 |
motor performance | 30 |
peroxisome proliferator | 30 |
intestinal microbiota | 30 |
breast cancer | 30 |
informed consent | 30 |
allergic alveolitis | 29 |
diagnosed asthma | 29 |
muscular dystrophy | 29 |
modifier genes | 29 |
pulmonary neuroendocrine | 29 |
angiotensin ii | 29 |
bronchial wall | 29 |
primary graft | 29 |
biofilm formation | 29 |
surgical resection | 29 |
per patient | 29 |
activated protein | 29 |
mediated gene | 29 |
older children | 29 |
radiation pneumonitis | 29 |
function impairment | 29 |
arterial oxygen | 29 |
remains unclear | 29 |
primary care | 29 |
invasive fungal | 29 |
acquired immunodeficiency | 29 |
clinical care | 29 |
large airways | 29 |
lung organoids | 29 |
many studies | 29 |
advanced lung | 29 |
normal human | 29 |
treatment options | 29 |
previously shown | 29 |
transgene expression | 29 |
different types | 29 |
exogenous surfactant | 29 |
natural history | 29 |
opportunistic infections | 29 |
early detection | 29 |
sublobar resection | 29 |
positive correlation | 29 |
tumour necrosis | 29 |
methenamine silver | 29 |
light microscopy | 29 |
working formulation | 29 |
patient outcomes | 29 |
fl aky | 29 |
pulmonary immune | 29 |
hiv infection | 29 |
lung tumor | 29 |
within hours | 29 |
genes involved | 29 |
first years | 29 |
day mortality | 29 |
bronchiolar epithelium | 29 |
transfection efficiency | 29 |
toxicologic study | 29 |
stage i | 29 |
induced pluripotent | 29 |
ventricular septal | 29 |
cellular rejection | 29 |
lung surfactant | 29 |
sputum induction | 28 |
infectious agents | 28 |
acute inflammation | 28 |
induced inflammation | 28 |
north america | 28 |
peripheral lung | 28 |
alveolar capillaries | 28 |
effi cacy | 28 |
patients compared | 28 |
novel therapeutic | 28 |
abdominal pain | 28 |
release ventilation | 28 |
diffi culty | 28 |
may reduce | 28 |
alveolar collapse | 28 |
tumor cell | 28 |
air spaces | 28 |
older people | 28 |
neutrophilic inflammation | 28 |
lung may | 28 |
poor asthma | 28 |
also play | 28 |
right ventricle | 28 |
sleep disordered | 28 |
asm cell | 28 |
monoclonal antibodies | 28 |
old woman | 28 |
pressure release | 28 |
stage iii | 28 |
also showed | 28 |
muscle weakness | 28 |
chronic airway | 28 |
small molecules | 28 |
well established | 28 |
serum samples | 28 |
clinically stable | 28 |
specifi city | 28 |
diagnostic imaging | 28 |
aeruginosa infection | 28 |
infected macaques | 28 |
lesser extent | 28 |
enzootic pneumonia | 28 |
club cells | 28 |
cells following | 28 |
free survival | 28 |
respiratory epithelial | 28 |
pregnant women | 28 |
new insights | 28 |
patients showed | 28 |
cftr mutation | 28 |
analysed using | 28 |
lung recruitment | 28 |
minute walk | 28 |
lung dcs | 28 |
many cases | 28 |
significant role | 28 |
million people | 28 |
diffuse pulmonary | 27 |
studies showed | 27 |
thoracic surgery | 27 |
clara cell | 27 |
autoimmune disease | 27 |
parietal pleura | 27 |
otitis media | 27 |
immunosorbent assay | 27 |
endotracheal tube | 27 |
total protein | 27 |
directed differentiation | 27 |
lung regions | 27 |
tuberculosis infection | 27 |
healthy individuals | 27 |
human pluripotent | 27 |
three major | 27 |
matrix metalloproteinase | 27 |
combination therapy | 27 |
will also | 27 |
cell fate | 27 |
case reports | 27 |
mm hg | 27 |
three cases | 27 |
pathogenic bacteria | 27 |
vas deferens | 27 |
general practice | 27 |
ct image | 27 |
lung stress | 27 |
two major | 27 |
nasal epithelium | 27 |
epithelial injury | 27 |
waiting list | 27 |
lymphocytic bronchiolitis | 27 |
immune status | 27 |
significantly elevated | 27 |
arachidonic acid | 27 |
median time | 27 |
minimally invasive | 27 |
based therapy | 27 |
suppurative bronchopneumonia | 27 |
closely related | 27 |
hospital stay | 27 |
cmv disease | 27 |
test results | 27 |
assessed using | 27 |
cystic fi | 27 |
carinii pneumonia | 27 |
pulmonary capillary | 27 |
acute cellular | 27 |
may affect | 27 |
expression level | 27 |
fgl expression | 27 |
high prevalence | 27 |
targeted delivery | 27 |
asthma patients | 27 |
human alveolar | 27 |
lung disorders | 27 |
release phase | 27 |
mechanical properties | 27 |
will provide | 27 |
traction bronchiectasis | 27 |
respiratory muscles | 27 |
ionizing radiation | 27 |
chapel hill | 27 |
common marmosets | 27 |
negative pressure | 27 |
large fl | 27 |
whole lung | 27 |
literature review | 27 |
may present | 27 |
resident memory | 27 |
time point | 26 |
cftr chloride | 26 |
bronchial obstruction | 26 |
studies will | 26 |
factor alpha | 26 |
oleic acid | 26 |
clinic visits | 26 |
underlying disease | 26 |
aerosol delivery | 26 |
inducible nitric | 26 |
atp release | 26 |
airway tree | 26 |
therapeutic effect | 26 |
patients diagnosed | 26 |
distal airways | 26 |
gene mutations | 26 |
pulmonary nodules | 26 |
insulin resistance | 26 |
nl min | 26 |
virulence factors | 26 |
may include | 26 |
coronavirus infection | 26 |
preliminary data | 26 |
respiratory disorders | 26 |
consensus statement | 26 |
two main | 26 |
fibrinous bronchopneumonia | 26 |
donor lung | 26 |
lower levels | 26 |
will focus | 26 |
lung toxicity | 26 |
serous cells | 26 |
single dose | 26 |
alveolar surface | 26 |
tube placement | 26 |
therapeutic agents | 26 |
patients also | 26 |
cell growth | 26 |
studies may | 26 |
elevated levels | 26 |
also associated | 26 |
bronchial pneumonia | 26 |
receptor antagonist | 26 |
sectional study | 26 |
particle size | 26 |
ventilatory support | 26 |
recent advances | 26 |
extrinsic allergic | 26 |
target cells | 26 |
marginated neutrophils | 26 |
ventilator settings | 26 |
inclusion bodies | 26 |
pleural plaques | 26 |
viral respiratory | 26 |
increased numbers | 26 |
fetal lung | 26 |
lobar pneumonia | 26 |
surface expression | 26 |
ii cell | 26 |
inflammatory effects | 26 |
large quantity | 26 |
collagen vascular | 26 |
significantly less | 26 |
electron microscopic | 26 |
gross lesions | 26 |
mesenchymal transition | 26 |
age range | 26 |
congenital heart | 26 |
multivariate analysis | 26 |
intratracheal administration | 25 |
invasive ventilation | 25 |
remains controversial | 25 |
surfactant treatment | 25 |
immunodefi ciency | 25 |
real time | 25 |
cell migration | 25 |
fluid secretion | 25 |
changes may | 25 |
higher risk | 25 |
important roles | 25 |
blood gases | 25 |
related diseases | 25 |
derived mesenchymal | 25 |
consolidation opacity | 25 |
blood alcohol | 25 |
low birth | 25 |
pleural surface | 25 |
diagnostic accuracy | 25 |
disease process | 25 |
randomised controlled | 25 |
antisense oligonucleotides | 25 |
early phase | 25 |
four patients | 25 |
disseminated disease | 25 |
particulate matter | 25 |
inflammatory agents | 25 |
lung interstitium | 25 |
myeloid cells | 25 |
nasal potential | 25 |
low dose | 25 |
antibiotic use | 25 |
macrophage colony | 25 |
klebsiella pneumoniae | 25 |
may improve | 25 |
hiv infected | 25 |
pulmonary capillaries | 25 |
renal function | 25 |
exhaled nitric | 25 |
analysis revealed | 25 |
significant correlation | 25 |
rnai therapeutics | 25 |
allergic diseases | 25 |
complement activation | 25 |
granulomatous disease | 25 |
lung architecture | 25 |
distal airway | 25 |
lung fibroblasts | 25 |
mesenchymal cells | 25 |
bronchial brushing | 25 |
strongly associated | 25 |
factors associated | 25 |
also may | 25 |
clinical relevance | 25 |
may explain | 25 |
inflammatory properties | 25 |
skin lesions | 25 |
possible role | 25 |
high fat | 25 |
human embryonic | 25 |
lung adenocarcinomas | 25 |
partial pressure | 25 |
lymphoproliferative disorders | 25 |
i pneumonocytes | 25 |
factors include | 25 |
inflammatory drugs | 25 |
statistical significance | 25 |
surfactant material | 25 |
airway infl | 25 |
glucose tolerance | 25 |
situ hybridization | 25 |
following treatment | 25 |
tumor progression | 25 |
early lung | 25 |
currently available | 25 |
intravenous administration | 25 |
vascular endothelium | 25 |
entire lung | 25 |
right middle | 25 |
nasal cannula | 25 |
lower lungs | 25 |
control study | 24 |
organ dysfunction | 24 |
symptoms include | 24 |
mc sn | 24 |
cause pulmonary | 24 |
des arg | 24 |
bone mineral | 24 |
light source | 24 |
quality control | 24 |
induced apoptosis | 24 |
fvc ratio | 24 |
major role | 24 |
white blood | 24 |
usually present | 24 |
intercellular adhesion | 24 |
regression analysis | 24 |
cell suspensions | 24 |
wnt signaling | 24 |
systemic disease | 24 |
mesothelial cells | 24 |
bronchopulmonary aspergillosis | 24 |
macrophage polarization | 24 |
one third | 24 |
chloride secretion | 24 |
endotoxin levels | 24 |
odds ratios | 24 |
spontaneously breathing | 24 |
decreased lung | 24 |
asl height | 24 |
lung sags | 24 |
port hedland | 24 |
analysis showed | 24 |
mucus secretion | 24 |
tissue injury | 24 |
urgent hcu | 24 |
transbronchial biopsies | 24 |
clinical diagnosis | 24 |
restrictive lung | 24 |
hla antibodies | 24 |
pulmonary macrophages | 24 |
care units | 24 |
asthma action | 24 |
free days | 24 |
inhibitory effects | 24 |
infi ltrates | 24 |
family members | 24 |
gut microbiome | 24 |
noninvasive ventilation | 24 |
lung health | 24 |
term outcomes | 24 |
significantly improved | 24 |
asthma management | 24 |
specific antibodies | 24 |
nasal passages | 24 |
interstitial edema | 24 |
last years | 24 |
measles virus | 24 |
clinical implications | 24 |
body composition | 24 |
asthma candidate | 24 |
palliative care | 24 |
isolated lung | 24 |
post infection | 24 |
medication use | 24 |
therapeutic intervention | 24 |
positive control | 24 |
airway cells | 24 |
wall thickness | 24 |
nitrogen dioxide | 24 |
oral antibiotics | 24 |
days post | 24 |
cell activation | 24 |
steroid therapy | 24 |
open lung | 24 |
alveolar edema | 24 |
pulmonary tb | 24 |
therapeutic effects | 24 |
inhaled particles | 24 |
na absorption | 24 |
asthma education | 24 |
myocardial infarction | 24 |
autoimmune diseases | 24 |
fi brous | 24 |
patient registry | 24 |
may indicate | 24 |
drug development | 24 |
drug toxicity | 24 |
well understood | 24 |
lactate dehydrogenase | 24 |
granulomatous pneumonia | 24 |
improved lung | 24 |
gold stage | 24 |
primary outcome | 24 |
delayed diagnosis | 24 |
effective treatment | 24 |
heme oxygenase | 24 |
critical illness | 24 |
will allow | 24 |
fibrosis lung | 24 |
retrospective cohort | 24 |
nucleotide binding | 24 |
inspired oxygen | 24 |
male patient | 23 |
ozone therapy | 23 |
also demonstrated | 23 |
new york | 23 |
response rate | 23 |
airway narrowing | 23 |
line treatment | 23 |
pulmonary vasculature | 23 |
systemic circulation | 23 |
higher incidence | 23 |
house dust | 23 |
common causes | 23 |
day post | 23 |
mucus production | 23 |
tissue repair | 23 |
randomized trial | 23 |
pneumocystis pneumonia | 23 |
cftr trafficking | 23 |
interstitial macrophages | 23 |
diagnostic yield | 23 |
mast cell | 23 |
bordetella bronchiseptica | 23 |
studies using | 23 |
inflammatory disease | 23 |
study aims | 23 |
terminal bronchioles | 23 |
bacterial clearance | 23 |
clinical use | 23 |
soluble factors | 23 |
sputum production | 23 |
inhaled protein | 23 |
one case | 23 |
may serve | 23 |
mechanisms underlying | 23 |
infective endocarditis | 23 |
autosomal recessive | 23 |
time course | 23 |
suppurative lung | 23 |
sars coronavirus | 23 |
less severe | 23 |
peak expiratory | 23 |
mechanisms involved | 23 |
two types | 23 |
therapeutic strategy | 23 |
genetic factors | 23 |
first two | 23 |
pulmonary interstitium | 23 |
flow nasal | 23 |
cellular debris | 23 |
multiple organs | 23 |
lung structure | 23 |
aspergillus spp | 23 |
dna nanoparticles | 23 |
functional cftr | 23 |
one week | 23 |
surfactant replacement | 23 |
muscle strength | 23 |
nsclc patients | 23 |
tumor microenvironment | 23 |
targeted therapy | 23 |
study also | 23 |
two distinct | 23 |
chart review | 23 |
corticosteroid therapy | 23 |
reference values | 23 |
advanced non | 23 |
human cells | 23 |
predictive value | 23 |
olfactory epithelium | 23 |
protein synthesis | 23 |
working group | 23 |
may mimic | 23 |
normal values | 23 |
transpulmonary pressure | 23 |
beneficial effect | 23 |
related lung | 23 |
play important | 23 |
control groups | 23 |
first days | 23 |
fi eld | 23 |
diffuse ground | 23 |
control cells | 23 |
asbestos bodies | 23 |
years ago | 23 |
endothelial permeability | 23 |
androgen receptor | 23 |
venous blood | 23 |
asthma medication | 23 |
various lung | 23 |
cancer risk | 23 |
cancer therapy | 23 |
clinical application | 23 |
independently associated | 23 |
health status | 23 |
important cause | 23 |
rna delivery | 23 |
healthy volunteers | 23 |
high incidence | 23 |
imaging findings | 23 |
associated virus | 23 |
much higher | 23 |
lung axis | 23 |
maintenance therapy | 23 |
virus pneumonia | 23 |
antifungal prophylaxis | 22 |
increased pulmonary | 22 |
respiratory society | 22 |
results patients | 22 |
resonance imaging | 22 |
significant change | 22 |
experimental models | 22 |
linear regression | 22 |
macrophage function | 22 |
quality improvement | 22 |
blood cultures | 22 |
atypical pneumonia | 22 |
morphologic features | 22 |
new therapies | 22 |
cell survival | 22 |
neuroendocrine cells | 22 |
total rna | 22 |
egfr mutations | 22 |
useful tool | 22 |
prostate cancer | 22 |
stable copd | 22 |
histological examination | 22 |
mrna levels | 22 |
alveolar recruitment | 22 |
recruitment maneuvers | 22 |
later stages | 22 |
individual patient | 22 |
biopsy specimens | 22 |
lesions may | 22 |
mice exposed | 22 |
intratracheal instillation | 22 |
endotracheal intubation | 22 |
bacterial colonization | 22 |
sputum culture | 22 |
high doses | 22 |
immune homeostasis | 22 |
umbilical cord | 22 |
foreign material | 22 |
retrospective review | 22 |
infi ltrative | 22 |
minute ventilation | 22 |
therapeutic efficacy | 22 |
also shown | 22 |
early studies | 22 |
antimicrobial activity | 22 |
also contribute | 22 |
old female | 22 |
study demonstrated | 22 |
healthy donors | 22 |
recurrent infections | 22 |
dead space | 22 |
systemic administration | 22 |
human leukocyte | 22 |
lung regeneration | 22 |
human influenza | 22 |
vast majority | 22 |
acting beta | 22 |
well known | 22 |
right heart | 22 |
european respiratory | 22 |
drug administration | 22 |
methods data | 22 |
independent predictors | 22 |
preclinical studies | 22 |
presenting cells | 22 |
proinflammatory cytokine | 22 |
bilateral lung | 22 |
usually occurs | 22 |
six patients | 22 |
rapidly progressive | 22 |
asthma exacerbation | 22 |
gel electrophoresis | 22 |
bronchopleural fistula | 22 |
may involve | 22 |
glass liked | 22 |
life expectancy | 22 |
special stains | 22 |
lung stem | 22 |
chemokine receptor | 22 |
bacterial pathogens | 22 |
like receptors | 22 |
dry weight | 22 |
cytokine release | 22 |
cell damage | 22 |
blood cell | 22 |
massive fibrosis | 22 |
miliary tuberculosis | 22 |
mg day | 22 |
premature infants | 22 |
human monocyte | 22 |
results show | 22 |
fl ow | 22 |
airway secretions | 22 |
odds ratio | 22 |
oral bacteriotherapy | 22 |
classifi cation | 22 |
hospital admissions | 22 |
infected animals | 22 |
lung cell | 22 |
asbestos fibres | 22 |
hypoxemic respiratory | 22 |
may reveal | 22 |
calculated using | 21 |
national institutes | 21 |
simplex virus | 21 |
improve lung | 21 |
past years | 21 |
cpap therapy | 21 |
increased lung | 21 |
air leak | 21 |
nontuberculous mycobacteria | 21 |
allow us | 21 |
increased susceptibility | 21 |
fatal cases | 21 |
protein concentration | 21 |
airway hyperreactivity | 21 |
lung deposition | 21 |
portal hypertension | 21 |
congestive heart | 21 |
care centers | 21 |
pneumocystis jiroveci | 21 |
normal breathing | 21 |
clinical information | 21 |
alveolar ducts | 21 |
dna damage | 21 |
human primates | 21 |
dust pneumoconiosis | 21 |
superior vena | 21 |
data analysis | 21 |
acute renal | 21 |
muscle mass | 21 |
studies demonstrated | 21 |
similar results | 21 |
mouse lungs | 21 |
signal transduction | 21 |
gram stain | 21 |
neuroendocrine tumors | 21 |
follow procedures | 21 |
vascular disease | 21 |
surfactant therapy | 21 |
blood test | 21 |
high expression | 21 |
fluorescent protein | 21 |
graft failure | 21 |
airway mucus | 21 |
mediated immunity | 21 |
bronchial tree | 21 |
corticosteroid treatment | 21 |
culture models | 21 |
clinical disease | 21 |
patients experience | 21 |
pleural fl | 21 |
many different | 21 |
inflammatory reaction | 21 |
swine influenza | 21 |
mycobacterial infection | 21 |
fast bacilli | 21 |
histologic features | 21 |
allergic rhinitis | 21 |
healthy adults | 21 |
competing interests | 21 |
lung immune | 21 |
aortic arch | 21 |
time rt | 21 |
significantly greater | 21 |
pain management | 21 |
mycobacterium abscessus | 21 |
classifi ed | 21 |
paranasal sinuses | 21 |
lung repair | 21 |
hrct scans | 21 |
mitochondrial calcium | 21 |
interstitial fi | 21 |
mice immunized | 21 |
host defence | 21 |
occlusive disease | 21 |
cells via | 21 |
acid phosphatase | 21 |
cell adhesion | 21 |
baseline fev | 21 |
brain metastasis | 21 |
breathing pattern | 21 |
fibroblastic foci | 21 |
current smokers | 21 |
airway volume | 21 |
clinical significance | 21 |
blood monocytes | 21 |
lymphoid cells | 21 |
blood glucose | 21 |
patients completed | 21 |
negative correlation | 21 |
must also | 21 |
atp binding | 21 |
defense mechanism | 21 |
binding domain | 21 |
pathological findings | 21 |
pneumocyte hyperplasia | 21 |
sensitive asthma | 21 |
better understand | 21 |
emphysema severity | 21 |
function test | 21 |
crucial role | 21 |
host immune | 21 |
lung immunity | 21 |
expiratory time | 21 |
oesophageal reflux | 21 |
small intestine | 21 |
gut microbiota | 21 |
without asthma | 20 |
may prove | 20 |
drug therapy | 20 |
anticancer drug | 20 |
may take | 20 |
newly diagnosed | 20 |
acquired respiratory | 20 |
causative agent | 20 |
like opacity | 20 |
weeks gestation | 20 |
secretory cells | 20 |
previous months | 20 |
whole blood | 20 |
last year | 20 |
capillary endothelium | 20 |
alveolar surfactant | 20 |
naked rna | 20 |
pleural line | 20 |
optical density | 20 |
therapeutic options | 20 |
rarely seen | 20 |
refl ux | 20 |
among others | 20 |
retinoic acid | 20 |
genes associated | 20 |
also important | 20 |
immune function | 20 |
alveolar interstitium | 20 |
neuroendocrine cell | 20 |
will help | 20 |
primary cells | 20 |
vascular resistance | 20 |
expression patterns | 20 |
recent evidence | 20 |
parenchymal lung | 20 |
expression profiles | 20 |
blood vessel | 20 |
may need | 20 |
dust particles | 20 |
immune complex | 20 |
centrilobular nodules | 20 |
delivered dose | 20 |
drug reaction | 20 |
injured mice | 20 |
patient care | 20 |
mucociliary transport | 20 |
antigen presentation | 20 |
high frequency | 20 |
previously demonstrated | 20 |
clinical utility | 20 |
urea nitrogen | 20 |
highly variable | 20 |
er stress | 20 |
western blotting | 20 |
single nucleotide | 20 |
registry data | 20 |
linked immunosorbent | 20 |
kidney disease | 20 |
tissue samples | 20 |
methods children | 20 |
body size | 20 |
interstitial emphysema | 20 |
lung resections | 20 |
bronchodilator effect | 20 |
also called | 20 |
cytokine chemokine | 20 |
advanced glycation | 20 |
new therapeutic | 20 |
cause severe | 20 |
candidate genes | 20 |
lining fluid | 20 |
promising results | 20 |
generation sequencing | 20 |
needle aspiration | 20 |
specific cd | 20 |
may require | 20 |
disease associated | 20 |
ozone oxidative | 20 |
total number | 20 |
granuloma formation | 20 |
pulmonary defense | 20 |
relatively high | 20 |
phagocytic cells | 20 |
high altitude | 20 |
three months | 20 |
tight junctions | 20 |
killer cells | 20 |
fungal colonization | 20 |
chronic pain | 20 |
treatment strategies | 20 |
tissue disease | 20 |
surgical intervention | 20 |
drug discovery | 20 |
sleep apnoea | 20 |
progressive massive | 20 |
high level | 20 |
cell lymphoma | 20 |
high density | 20 |
silver stain | 20 |
clinically diagnosed | 20 |
neonatal respiratory | 20 |
pulmonary tissue | 20 |
intracellular calcium | 20 |
type iii | 20 |
clinical applications | 20 |
chronic eosinophilic | 20 |
based therapeutics | 20 |
multicenter study | 20 |
variable ventilation | 20 |
less commonly | 20 |
vascular smooth | 20 |
fibroblast growth | 20 |
severe exacerbations | 20 |
cftr inh | 20 |
severe sepsis | 20 |
blot analysis | 20 |
chest cavity | 20 |
secondary infection | 20 |
disease characterized | 20 |
fibrin deposition | 20 |
immune deficiency | 20 |
significant improvements | 20 |
alveolar capillary | 20 |
specific antibody | 20 |
avium complex | 20 |
msc administration | 20 |
cftr inhibitor | 20 |
short term | 20 |
membrane formation | 20 |
infected mice | 20 |
conducting system | 20 |
oxidative damage | 20 |
cftr mrna | 20 |
pulmonary symptoms | 20 |
type pneumocytes | 20 |
six months | 20 |
time period | 20 |
selected patients | 20 |
supplemental oxygen | 19 |
aids complicated | 19 |
hbe cells | 19 |
induced airway | 19 |
derived growth | 19 |
candida species | 19 |
reflux disease | 19 |
dental treatment | 19 |
remains neutral | 19 |
gold nanoparticles | 19 |
pulmonary dysfunction | 19 |
recruitment maneuver | 19 |
reference equations | 19 |
mature dcs | 19 |
study design | 19 |
moist rales | 19 |
succinate dehydrogenase | 19 |
increased density | 19 |
molecular basis | 19 |
cell recruitment | 19 |
associated protein | 19 |
urinary bladder | 19 |
may induce | 19 |
takes place | 19 |
oxidative preconditioning | 19 |
jurisdictional claims | 19 |
lung lavage | 19 |
pressure support | 19 |
tcav method | 19 |
unpublished data | 19 |
exclusion criteria | 19 |
days later | 19 |
retrospective analysis | 19 |
forced vital | 19 |
neutrophil apoptosis | 19 |
surfactant function | 19 |
breath sounds | 19 |
cftr tm | 19 |
body plethysmography | 19 |
routine clinical | 19 |
reticular pattern | 19 |
polymeric nanoparticles | 19 |
essential role | 19 |
eosinophilic lung | 19 |
fold higher | 19 |
induced asthma | 19 |
cellular infiltration | 19 |
small nodules | 19 |
low tidal | 19 |
circulating monocytes | 19 |
immunocompromised hosts | 19 |
preterm birth | 19 |
radiological findings | 19 |
guinea pig | 19 |
mycoplasma pneumoniae | 19 |
additional studies | 19 |
cell response | 19 |
abscess formation | 19 |
neonatal screening | 19 |
will need | 19 |
rapid progression | 19 |
infected avian | 19 |
manifestations include | 19 |
lung water | 19 |
changes include | 19 |
among lung | 19 |
clinical findings | 19 |
function parameters | 19 |
type iv | 19 |
fibrotic lung | 19 |
may influence | 19 |
institutional affiliations | 19 |
chronic bronchiolitis | 19 |
newborn infants | 19 |
primary tumor | 19 |
task force | 19 |
total body | 19 |
studies revealed | 19 |
increased morbidity | 19 |
clinical status | 19 |
lymphoid interstitial | 19 |
short circuit | 19 |
cell volume | 19 |
cytokine il | 19 |
diaphragmatic hernia | 19 |
mediated rejection | 19 |
confocal microscopy | 19 |
natriuretic peptide | 19 |
endogenous lipid | 19 |
systemic inflammatory | 19 |
fibrosis airway | 19 |
analyzed using | 19 |
lymphocyte count | 19 |
novel therapies | 19 |
lamina propria | 19 |
pack years | 19 |
tobacco smoking | 19 |
regional lymph | 19 |
coronary arteries | 19 |
springer nature | 19 |
boundary conditions | 19 |
bacterial killing | 19 |
chronic cases | 19 |
pulmonary eosinophilia | 19 |
first described | 19 |
reduced levels | 19 |
channel gating | 19 |
published maps | 19 |
human body | 19 |
human monocytes | 19 |
ii alveolar | 19 |
statistical analyses | 19 |
isolated rat | 19 |
chest drainage | 19 |
international guidelines | 19 |
small quantity | 19 |
air quality | 19 |
progressive lung | 19 |
cytomegalovirus infection | 19 |
channel function | 19 |
asthma phenotypes | 19 |
target genes | 19 |
mycobacterium avium | 19 |
haemophilus influenzae | 19 |
laryngeal closure | 19 |
developing countries | 19 |
mitochondrial dysfunction | 19 |
neutrophil infiltration | 19 |
total cell | 19 |
term follow | 19 |
pleural thickening | 19 |
several years | 19 |
nature remains | 19 |
older patients | 19 |
obstructive pneumonia | 19 |
clinical impact | 19 |
increasing evidence | 19 |
buffered saline | 19 |
diagnostic tests | 19 |
underlying cause | 19 |
left side | 19 |
negative bacteria | 19 |
months prior | 19 |
bronchointerstitial pneumonia | 19 |
histoplasma capsulatum | 19 |
cfu ml | 19 |
within weeks | 19 |
syndrome pulmonary | 19 |
drug reactions | 19 |
twice daily | 19 |
hospital mortality | 19 |
lung recipients | 19 |
results demonstrate | 19 |
low temperature | 19 |
cases showed | 19 |
exosomes isolated | 19 |
candida albicans | 19 |
respiratory illness | 19 |
macrophage phenotype | 19 |
pneumoniae infection | 19 |
studies investigating | 19 |
foamy macrophages | 19 |
reverse transcription | 19 |
underlying lung | 19 |
fluid clearance | 18 |
reduces lung | 18 |
repeated measures | 18 |
pneumococcal pneumonia | 18 |
exudative phase | 18 |
class ii | 18 |
decay rate | 18 |
microvascular permeability | 18 |
airway mucosa | 18 |
information regarding | 18 |
imaging demonstrations | 18 |
lung macrophage | 18 |
may increase | 18 |
injury caused | 18 |
inhaled corticosteroid | 18 |
community acquired | 18 |
antigen challenge | 18 |
study lung | 18 |
differentiation protocols | 18 |
different clinical | 18 |
percent change | 18 |
imaging fi | 18 |
protein therapeutics | 18 |
skin test | 18 |
heat shock | 18 |
pathologic changes | 18 |
injury following | 18 |
related quality | 18 |
lymphocytic bronchitis | 18 |
walk test | 18 |
null mice | 18 |
serum albumin | 18 |
disseminated intravascular | 18 |
defi nitive | 18 |
plasma levels | 18 |
airway distensibility | 18 |
injury model | 18 |
urinary tract | 18 |
antibiotic resistance | 18 |
residual volume | 18 |
surfactant administration | 18 |
blood mononuclear | 18 |
meconium ileus | 18 |
lung cd | 18 |
lung inflammatory | 18 |
ml min | 18 |
interstitial infiltrates | 18 |
inhaled steroids | 18 |
apoptotic cell | 18 |
months later | 18 |
pneumonia may | 18 |
ii clinical | 18 |
published data | 18 |
patients using | 18 |
days following | 18 |
membrane expression | 18 |
findings may | 18 |
patients attending | 18 |
pediatric ild | 18 |
healthy lungs | 18 |
hela cells | 18 |
end stage | 18 |
average age | 18 |
year follow | 18 |
differ significantly | 18 |
lung aeration | 18 |
histologic sections | 18 |
also occurs | 18 |
nine patients | 18 |
chronic suppurative | 18 |
ussing chamber | 18 |
part ii | 18 |
blood eosinophilia | 18 |
breathing effort | 18 |
decreased expression | 18 |
healthy control | 18 |
cardiopulmonary bypass | 18 |
function decline | 18 |
patients referred | 18 |
basal cell | 18 |
study suggests | 18 |
binding domains | 18 |
underlying mechanisms | 18 |
also detected | 18 |
squamous epithelium | 18 |
host cell | 18 |
antibiotic exposure | 18 |
right side | 18 |
general hospital | 18 |
lung protective | 18 |
epithelial barrier | 18 |
treatment groups | 18 |
glycation end | 18 |
national health | 18 |
microbiologic study | 18 |
cell metaplasia | 18 |
transplant rejection | 18 |
gastric aspiration | 18 |
metabolic pathways | 18 |
might also | 18 |
acute asthma | 18 |
cells using | 18 |
scanning demonstrates | 18 |
vascular tone | 18 |
pulmonary inflammatory | 18 |
mtb infection | 18 |
bovine serum | 18 |
intravenous antibiotics | 18 |
tubercle bacilli | 18 |
never smokers | 18 |
mycobacterium bovis | 18 |
muscarinic receptors | 18 |
data collection | 18 |
induced fibrosis | 18 |
postoperative period | 18 |
lung progenitors | 18 |
viral cytopathic | 18 |
international recommendations | 18 |
mice infected | 18 |
alveolar lining | 18 |
early recognition | 18 |
varying degrees | 18 |
ray demonstrated | 18 |
lung clearance | 18 |
granulocyte macrophage | 18 |
phosphorylated stat | 18 |
fully understood | 18 |
langerhans cells | 18 |
including lung | 18 |
disease progresses | 18 |
kinase inhibitors | 18 |
ii pneumocyte | 18 |
proximal airway | 18 |
diagnostic value | 18 |
epithelial lining | 18 |
vivo model | 18 |
signifi cance | 18 |
activated macrophages | 18 |
culture positive | 18 |
immunohistochemical staining | 18 |
pulmonary abscesses | 18 |
much less | 18 |
clinical problems | 18 |
mice treated | 18 |
fibrosing alveolitis | 18 |
intestinal tract | 18 |
respiratory events | 18 |
last decade | 18 |
dextran nanogels | 18 |
including asthma | 18 |
lung alveolar | 18 |
ethnic differences | 18 |
plasminogen activator | 18 |
delivery efficiency | 18 |
fio ratio | 18 |
direct contact | 18 |
potentially fatal | 18 |
exogenous lipid | 18 |
virus type | 18 |
nodular shadows | 18 |
lung strain | 17 |
intravascular coagulation | 17 |
molecular biology | 17 |
percentage change | 17 |
chester disease | 17 |
locally advanced | 17 |
allergic sensitization | 17 |
may modulate | 17 |
myristate acetate | 17 |
leukocyte antigen | 17 |
reported asthma | 17 |
rat alveolar | 17 |
first case | 17 |
randomly selected | 17 |
also noted | 17 |
alternative splicing | 17 |
systemic symptoms | 17 |
inflammatory stimuli | 17 |
independent risk | 17 |
eight patients | 17 |
lung model | 17 |
also show | 17 |
pulmonary fungal | 17 |
endogenous surfactant | 17 |
alveolar structure | 17 |
photon excitation | 17 |
direct effect | 17 |
associated pulmonary | 17 |
cross sectional | 17 |
also affect | 17 |
patients will | 17 |
cigarette use | 17 |
lung zones | 17 |
short telomeres | 17 |
observation period | 17 |
vascular rejection | 17 |
meconium aspiration | 17 |
respiratory questionnaire | 17 |
male patients | 17 |
serum proteins | 17 |
pulmonary epithelial | 17 |
inspiratory effort | 17 |
granulomatous inflammation | 17 |
incidence rate | 17 |
activating factor | 17 |
product use | 17 |
pneumonia severity | 17 |
compromised immunity | 17 |
study found | 17 |
targeted drug | 17 |
proteolytic enzymes | 17 |
highly expressed | 17 |
medical research | 17 |
cell wall | 17 |
pulmonary allograft | 17 |
mucus hypersecretion | 17 |
current knowledge | 17 |
right sided | 17 |